Dr. Bashir is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Unit 423
Houston, TX 77030Phone+1 713-794-5745Fax+1 713-794-4902
Education & Training
- University of ColoradoFellowship, Hematology and Medical Oncology, 2006 - 2009
- University of Missouri-ColumbiaResidency, Internal Medicine, 2003 - 2006
- King Edward Medical UniversityClass of 2001
Certifications & Licensure
- FL State Medical License 2021 - Present
- WA State Medical License 2023 - 2026
- AZ State Medical License 2023 - 2025
- GA State Medical License 2023 - 2025
- LA State Medical License 2023 - 2025
- MS State Medical License 2023 - 2025
- OK State Medical License 2020 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT) Start of enrollment: 2014 Jan 01
- Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation Start of enrollment: 2019 Oct 09
Publications & Presentations
PubMed
- 17 citationsBone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide.Rohtesh S. Mehta, Rima M. Saliba, Leonard C. Alsfeld, Jeffrey L. Jorgensen, Sa A. Wang
Transplantation and Cellular Therapy. 2021-09-16 - 51 citationsDecrease post-transplant relapse using donor-derived expanded NK-cells.Stefan O. Ciurea, Piyanuch Kongtim, Doris Soebbing, Prashant Trikha, Gregory K. Behbehani
Leukemia. 2021-07-26 - 31 citationsOutcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell TransplantationSyed Mohammad Ali Kazmi, Maliha Nusrat, Hilal Gunaydin, Amanda Cornelison, Nina Shah
Clinical Lymphoma, Myeloma & Leukemia. 2013-11-15
Journal Articles
- Primary Plasma Cell Leukemia: Autologous Stem Cell Transplant in an Era of Novel Induction DrugsKrina Patel, Rohtesh Mehta, Donna M Weber, Sheeba K Thomas, Nina Shah, Hans C Lee, Elisabet E Manasanch, Muzaffar H Qazilbash, Qaiser Bashir, Simrit Parmar, Robert Z O..., Nature
- Impact of a Novel Prognostic Model, Hematopoietic Cell Transplant-Composite Risk (HCT-CR), on Allogeneic Transplant Outcomes in Patients with Acute Myeloid Leukemia an...Uday Popat, Chitra M Hosing, Issa Khouri, Richard Champlin, Simrit Parmar, Partow Kebriaei, Borje S Andersson, Qaiser Bashir, Amin Alousi, Nature
Press Mentions
- Busulfan Added to Conditioning Regimen Effective for Newly Diagnosed MyelomaMay 20th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: